Phase 2 Study of Weekly Oxaliplatin and Capecitabine (XELOX) in Combination With Preoperative Radiotherapy in Patients With MRI Defined Locally Advanced Rectal Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
MRI staging and TME surgery
within 4 - 6 weeks after completion XELOX-RT
No
Jean-Philippe Aussel
Study Director
Sanofi
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
C_8601
NCT00174616
July 2003
November 2007
Name | Location |
---|